Thermo Fisher Scientific agreed to acquire Clario in a deal valued at about $9 billion, expanding its clinical‑trial software and data-management capabilities. Clario provides endpoint data capture and trial analytics that complement Thermo Fisher’s existing CRO assets, notably PPD, acquired in 2021. The buy will integrate Clario’s software for collecting and analyzing clinical endpoint data with Thermo Fisher’s lab services and CRO footprint, positioning the buyer to offer a more vertically integrated clinical development stack. Analysts flagged the deal as a strategic move to capture more of trial‑workflow value and to accelerate data‑driven trial design and execution. The transaction underscores continued M&A activity as diagnostics, lab services, and clinical‑data platforms converge to streamline drug development and cut trial timelines.